Poseida Therapeutics
(NASDAQ:PSTX)
$2.75
-0.03[-1.08%]
At close: Jun 24
$2.75
0.05[1.82%]
After Hours: 9:25AM EDT
Consensus Rating1
Overweight
Highest Price Target1
$24.00
Lowest Price Target1
$10.00
Consensus Price Target1
$16.60

Poseida Therapeutics (NASDAQ:PSTX) Stock, Analyst Ratings, Price Targets, Predictions

Poseida Therapeutics Inc has a consensus price target of $16.6, established from looking at the 17 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on May 22, 2024, May 2, 2024, and April 22, 2024. With an average price target of $20 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 614.29% upside for Poseida Therapeutics Inc from these 3 analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Mar
0
0
0
0
Apr
0
0
0
0
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Piper Sandler
Cantor Fitzgerald
HC Wainwright & Co.
Cantor Fitzgerald

1calculated from analyst ratings

Analyst Ratings for Poseida Therapeutics

Buy NowGet Alert
05/22/2024Buy Now614.29%HC Wainwright & Co.
Arthur He
→ $20ReiteratesBuy → BuyGet Alert
05/02/2024Buy Now614.29%HC Wainwright & Co.
Arthur He
→ $20ReiteratesBuy → BuyGet Alert
04/22/2024Buy Now614.29%HC Wainwright & Co.
Arthur He
→ $20ReiteratesBuy → BuyGet Alert
03/08/2024Buy Now614.29%HC Wainwright & Co.
Arthur He
→ $20ReiteratesBuy → BuyGet Alert
12/11/2023Buy Now257.14%Piper Sandler
Edward Tenthoff
$8 → $10MaintainsOverweightGet Alert
12/11/2023Buy Now614.29%HC Wainwright & Co.
Arthur He
$15 → $20MaintainsBuyGet Alert
10/10/2023Buy Now400%Cantor Fitzgerald
Jennifer Kim
→ $14ReiteratesOverweight → OverweightGet Alert
08/08/2023Buy Now435.71%HC Wainwright & Co.
Arthur He
→ $15ReiteratesBuy → BuyGet Alert
05/23/2023Buy Now435.71%HC Wainwright & Co.
Arthur He
→ $15ReiteratesBuy → BuyGet Alert
05/10/2023Buy Now435.71%HC Wainwright & Co.
Arthur He
→ $15Reiterates → BuyGet Alert
03/10/2023Buy Now435.71%HC Wainwright & Co.
Arthur He
→ $15Reiterates → BuyGet Alert
02/23/2023Buy Now435.71%HC Wainwright & Co.
Arthur He
→ $15MaintainsBuyGet Alert
02/01/2023Buy Now757.14%Cantor Fitzgerald
Jennifer Kim
→ $24Reiterates → OverweightGet Alert
01/04/2023Buy Now435.71%HC Wainwright & Co.
Swayampakula Ramakanth
→ $15Initiates → BuyGet Alert
08/09/2022Buy Now292.86%Piper Sandler
Edward Tenthoff
$9 → $11MaintainsOverweightGet Alert
05/13/2022Buy Now221.43%Piper Sandler
Edward Tenthoff
$19 → $9MaintainsOverweightGet Alert
01/07/2022Buy Now757.14%Cantor Fitzgerald
Brian Cheng
→ $24Initiates → OverweightGet Alert

FAQ

Q

What is the target price for Poseida Therapeutics (PSTX) stock?

A

The latest price target for Poseida Therapeutics (NASDAQ:PSTX) was reported by HC Wainwright & Co. on May 22, 2024. The analyst firm set a price target for $20.00 expecting PSTX to rise to within 12 months (a possible 614.29% upside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Poseida Therapeutics (PSTX)?

A

The latest analyst rating for Poseida Therapeutics (NASDAQ:PSTX) was provided by HC Wainwright & Co., and Poseida Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Poseida Therapeutics (PSTX)?

A

There is no last upgrade for Poseida Therapeutics

Q

When was the last downgrade for Poseida Therapeutics (PSTX)?

A

There is no last downgrade for Poseida Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Poseida Therapeutics (PSTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Poseida Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Poseida Therapeutics was filed on May 22, 2024 so you should expect the next rating to be made available sometime around May 22, 2025.

Q

Is the Analyst Rating Poseida Therapeutics (PSTX) correct?

A

While ratings are subjective and will change, the latest Poseida Therapeutics (PSTX) rating was a reiterated with a price target of $0.00 to $20.00. The current price Poseida Therapeutics (PSTX) is trading at is $2.80, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch